Replies to post #105563 on Biotech Values

[rwdm]

I am not sure that from a business standpoint PI-2302 is superfluous. It can be considered as a biobetter of Copaxone due to its improved bioavailability

[mouton29]

<<the Citizen Petition strikes me as a Hail Mary pass by Peptimmune to try to remain relevant (and stay out of bankruptcy).>>

You mean, by potentially slowing down or derailing generic Copaxone, they might encourage NVS to exercise the option?